The U.S. Food and Drug Administration (FDA) has posted on its Website a letter from a New Jersey-based pharmaceutical compounding facility recalling all of its compounded products due to their potential contamination with mold. According to the letter, the recall was instituted after Med Prep Consulting Inc. was notified by a Connecticut hospital that it had observed “visible particulate contaminants,” confirmed as mold, in 50 ml bags of Med Prep’s intravenous solution. FDA Center for Drug Evaluation and Research Director Janet Woodcock said, “We do not have reports of patient infections. However, due to a lack of sterility assurance at the facility and out of an abundance of caution, this recall is necessary to protect patients.” FDA has indicated that the investigation is continuing. See FDA News Release, March 18, 2013.